361 related articles for article (PubMed ID: 31013012)
1. Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review.
Kahn JS; Casseres RG; Her MJ; Dumont N; Gottlieb AB; Rosmarin D
J Drugs Dermatol; 2019 Apr; 18(4):. PubMed ID: 31013012
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
Takamura S; Sugai S; Taguchi R; Teraki Y
J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
[TBL] [Abstract][Full Text] [Related]
4. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
[TBL] [Abstract][Full Text] [Related]
5. Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
J Comp Eff Res; 2020 Aug; 9(11):767-779. PubMed ID: 32638609
[No Abstract] [Full Text] [Related]
6. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
[TBL] [Abstract][Full Text] [Related]
7. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
[TBL] [Abstract][Full Text] [Related]
8. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
Knuckles MLF; Levi E; Soung J
J Dermatolog Treat; 2019 Aug; 30(5):430-434. PubMed ID: 30339049
[No Abstract] [Full Text] [Related]
9. Real-World Experience With Apremilast in Treating Psoriasis.
Mayba JN; Gooderham MJ
J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization.
Poulin Y; Beauchemin C; Royer C; Gaudreau AJ; Yim C; Liu FF; Lachaine J
J Cutan Med Surg; 2020; 24(6):573-587. PubMed ID: 32597685
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
Ighani A; Georgakopoulos JR; Zhou LL; Walsh S; Shear N; Yeung J
J Cutan Med Surg; 2018; 22(3):290-296. PubMed ID: 29373924
[TBL] [Abstract][Full Text] [Related]
12. Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review.
Gyldenløve M; Alinaghi F; Zachariae C; Skov L; Egeberg A
Am J Clin Dermatol; 2022 Sep; 23(5):605-613. PubMed ID: 35737251
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
[No Abstract] [Full Text] [Related]
15. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis.
Bagel J; Nelson E; Keegan BR
J Drugs Dermatol; 2017 Oct; 16(10):957-962. PubMed ID: 29036248
[TBL] [Abstract][Full Text] [Related]
16. Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review.
Ghamrawi RI; Ghiam N; Wu JJ
J Dermatolog Treat; 2022 Feb; 33(1):94-99. PubMed ID: 32419531
[TBL] [Abstract][Full Text] [Related]
17. Real-world use of apremilast for patients with psoriasis in Japan.
Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
19. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
Danesh MJ; Beroukhim K; Nguyen C; Levin E; Koo J
Dermatol Online J; 2015 Jun; 21(6):. PubMed ID: 26158370
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]